• Jennifer J Lee, Jerri C Price, William M Jackson, Robert A Whittington, and IoannidisJohn P AJPADepartment of Medicine, Stanford Prevention Research Center.Departments of Epidemiology and Population Health.Biomedical Data Science.Statistics, Stanford University, and Meta-Research Innovation Center at Stanford (METRICS), Stanford,.
• Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY.
• J Neurosurg Anesthesiol. 2022 Jan 1; 34 (1): 107112107-112.

AbstractThe coronavirus disease 2019 (COVID-19) pandemic incited a global clinical trial research agenda of unprecedented speed and high volume. This expedited research activity in a time of crisis produced both successes and failures that offer valuable learning opportunities for the scientific community to consider. Successes include the implementation of large adaptive and pragmatic trials as well as burgeoning efforts toward rapid data synthesis and open science principles. Conversely, notable failures include: (1) inadequate study design and execution; (2) data reversal, fraud, and retraction; and (3) research duplication and waste. Other challenges that became highlighted were the need to find unbiased designs for investigating complex, nonpharmaceutical interventions and the use of routinely collected data for outcomes assessment. This article discusses these issues juxtaposing the COVID-19 trials experience against trials in anesthesiology and other fields. These lessons may serve as a positive catalyst for transforming future clinical trial research.Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

10 keywords...

hide…